The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VIR | -23.14% | -83.35% | -30.12% | -56% |
| S&P | +14.5% | +93.32% | +14.09% | +126% |
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
The biotech is out to prove that it isn't just a "pandemic stock."
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.21M | -60.5% |
| Gross Profit | -$1.71M | -38.6% |
| Gross Margin | -141.19% | -101.0% |
| Market Cap | $696.72M | -42.5% |
| Market Cap / Employee | $1.71M | 0.0% |
| Employees | 408 | -30.5% |
| Net Income | -$110.96M | 19.8% |
| EBITDA | -$105.69M | 15.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $299.32M | -3.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $93.41M | -1.7% |
| Short Term Debt | $8.83M | -54.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.45% | -13.8% |
| Return On Invested Capital | -11.82% | -0.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$122.76M | -56.4% |
| Operating Free Cash Flow | -$120.22M | -54.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.83 | 0.81 | 0.77 | 0.67 | -14.68% |
| Price to Sales | 13.02 | 13.53 | 42.70 | 36.73 | 138.91% |
| Price to Tangible Book Value | 0.85 | 0.83 | 0.79 | 0.68 | -14.82% |
| Enterprise Value to EBITDA | -0.62 | -1.11 | -0.72 | -1.00 | -22.71% |
| Return on Equity | -36.6% | -38.1% | -44.6% | -46.2% | 55.18% |
| Total Debt | $112.81M | $97.89M | $96.10M | $102.23M | -10.73% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
